{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:19:13Z","timestamp":1786735153350,"version":"build-2736575974"},"reference-count":64,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T00:00:00Z","timestamp":1676419200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2023,12,31]]},"DOI":"10.1080\/13696998.2023.2174748","type":"journal-article","created":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T09:37:42Z","timestamp":1675762662000},"page":"283-292","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":13,"title":["Cost-effectiveness of pembrolizumab as an adjuvant treatment for patients with resected stage IIB or IIC melanoma in Switzerland"],"prefix":"10.1080","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7276-9706","authenticated-orcid":false,"given":"Andrea","family":"Favre-Bulle","sequence":"first","affiliation":[{"name":"MSD, Lucerne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6293-8211","authenticated-orcid":false,"given":"Goran","family":"Bencina","sequence":"additional","affiliation":[{"name":"MSD, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8956-1725","authenticated-orcid":false,"given":"Shujing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc, Rahway, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1737-2989","authenticated-orcid":false,"given":"Ruixuan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc, Rahway, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8918-7777","authenticated-orcid":false,"given":"Daniel","family":"Andritschke","sequence":"additional","affiliation":[{"name":"MSD, Lucerne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1220-0731","authenticated-orcid":false,"given":"Arjun","family":"Bhadhuri","sequence":"additional","affiliation":[{"name":"Institute of Pharmaceutical Medicine (ECPM), University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,2,15]]},"reference":[{"key":"e_1_3_6_2_1","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1003a33"},{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2020.20388"},{"key":"e_1_3_6_4_1","unstructured":"Schweiz K. Krebs in der Schweiz: wichtige Zahlen. 2022. https:\/\/www.krebsliga.ch\/ueber-krebs\/zahlen-fakten\/-dl-\/fileadmin\/downloads\/sheets\/zahlen-krebs-in-der-schweiz.pdf"},{"key":"e_1_3_6_5_1","unstructured":"Skin Cancer Foundation. Melanoma stages diagnosis and staging. what it means for you. 2022. https:\/\/www.skincancer.org\/skin-cancer-information\/melanoma\/the-stages-of-melanoma\/"},{"key":"e_1_3_6_6_1","unstructured":"Melanoma Research Alliance. Stage 2 melanoma. 2022. https:\/\/www.curemelanoma.org\/about-melanoma\/melanoma-staging\/stage-2"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.2217\/mmt-2019-0022"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.26214"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2015.09.1139"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-018-6513-7"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz411"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2017.1343301"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.06.006"},{"key":"e_1_3_6_14_1","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology - Melanoma: Cutaneous. Version 1. 2022. NCCN https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cutaneous_melanoma.pdf"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15315"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.09.035"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.930"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0666"},{"key":"e_1_3_6_19_1","unstructured":"ClinicalTrials.gov. Safety and efficacy of pembrolizumab compared to placebo in resected high-risk stage II melanoma (MK-3475-716\/KEYNOTE-716). 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03553836"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00562-1"},{"key":"e_1_3_6_21_1","unstructured":"Food and Drug Administration. FDA approves pembrolizumab for adjuvant treatment of Stage IIB or IIC melanoma. 2022. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pembrolizumab-adjuvant-treatment-stage-iib-or-iic-melanoma#:\u223c:text=FDA%20approves%20pembrolizumab%20for%20adjuvant%20treatment%20of%20Stage%20IIB%20or%20IIC%20melanoma -Share&text=On%20December%203%2C%202021%2C%20the IIC%20melanoma%20following%20complete%20resection"},{"key":"e_1_3_6_22_1","unstructured":"European Medicines Agency. Product information. 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/keytruda-epar-product-information_en.pdf"},{"key":"e_1_3_6_23_1","unstructured":"RefData. Keytruda\u00ae product information (Switzerland). 2022. https:\/\/www.swissmedicinfo.ch\/#section1"},{"key":"e_1_3_6_24_1","unstructured":"Bundesamt f\u00fcr Gesundheit (BAG). BAG-bulletin. 2019. https:\/\/www.bag.admin.ch\/bag\/de\/home\/das-bag\/publikationen\/periodika\/bag-bulletin.html"},{"key":"e_1_3_6_25_1","unstructured":"ScienceIndustries Switzerland. Verhaltenskodex der pharmazeutischen Industrie in der Schweiz (Pharmakodex): Regel 26. 2022. https:\/\/www.scienceindustries.ch\/_file\/27931\/Pharmakodex_Version_Mai%202020_D.pdf"},{"key":"e_1_3_6_26_1","first-page":"w20170","article-title":"Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland,\" (in eng","volume":"149","author":"Bhadhuri A","year":"2019","unstructured":"Bhadhuri A, Insinga R, Guggisberg P, et\u00a0al. Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland,\" (in eng. Swiss Med Wkly. 2019;149:w20170.","journal-title":"Swiss Med Wkly"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-021-01398-7"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-021-01023-8"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-021-01396-9"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.07.001"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx133"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.07.011"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-13-13"},{"key":"e_1_3_6_34_1","unstructured":"National Institute for Health and Care Excellence. DSU technical support document 19: partitioned survival analysis for decision modelling in health care: a critical review. 2022. https:\/\/www.sheffield.ac.uk\/nice-dsu"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaa008"},{"key":"e_1_3_6_36_1","first-page":"3755","volume-title":"Future Oncol","author":"Samlowski W","year":"2022","unstructured":"Samlowski W, Silver MA, Hohlbauch A, et\u00a0al. Real-world clinical outcomes of patients with stage IIB and IIC cutaneous melanoma treated at US community oncology clinics. Future Oncol. 2022;18(33):3755\u20133767."},{"key":"e_1_3_6_37_1","unstructured":"Chaudhuri M. Utility Analysis report for KN716-CSR3 Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High-risk Stage II Melanoma: report adapted for Germany. 2022."},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2010.00700.x"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-018-0615-8"},{"key":"e_1_3_6_40_1","unstructured":"F. S. Office. Consumer prices. 2022. https:\/\/www.bfs.admin.ch\/bfs\/de\/home\/statistiken\/preise\/landesindex-konsumentenpreise.assetdetail.21784714.html"},{"key":"e_1_3_6_41_1","unstructured":"Larkin A Algurafi A Barlow B. Position paper: follow-up of high risk cutaneous melanoma in the UK. 2022. https:\/\/melanomafocus.org\/melanoma-patient-treatment-guide\/"},{"key":"e_1_3_6_42_1","unstructured":"National Institute for Health and Care Excellence. Melanoma: assessment and management: NICE guideline [NG14]. 2022. https:\/\/www.nice.org.uk\/guidance\/ng14"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.06.011"},{"key":"e_1_3_6_44_1","unstructured":"Aguiar-Ib\u00e1\u00f1ez R Wang J Bensimon A et\u00a0al. Challenges and good practices when modeling CostEffectiveness of novel (neo-) adjuvant oncology therapies in health technology appraisals (HTAs). ISPOR Workshop. 2020."},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2004.74005.x"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.10.7284"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602973"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(00)00304-X"},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.6.2351"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0172731"},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-014-2950-6"},{"key":"e_1_3_6_52_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-0379"},{"key":"e_1_3_6_53_1","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2021-108062"},{"key":"e_1_3_6_54_1","unstructured":"U.S. Department of Veterans Affairs. Measuring costs for cost-effectiveness analysis. 2022. https:\/\/www.herc.research.va.gov\/include\/page.asp?id=measure-costs-cea"},{"key":"e_1_3_6_55_1","doi-asserted-by":"crossref","unstructured":"Khattak MA Luke JJ Long GV et\u00a0al. Health-related quality of life (HRQoL) with pembrolizumab (pembro) in resected high-risk stage II melanoma in the phase 3 KEYNOTE-716 study. American Society of Clinical Oncology. 2022.","DOI":"10.1200\/JCO.2022.40.16_suppl.9581"},{"key":"e_1_3_6_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00081-4"},{"issue":"11","key":"e_1_3_6_57_1","first-page":"673","article-title":"Methods for the economic evaluation of health care interventions for priority setting in the health system: an update from WHO CHOICE","volume":"10","author":"Bertram MY","year":"2021","unstructured":"Bertram MY, Lauer JA, Stenberg K, et\u00a0al. Methods for the economic evaluation of health care interventions for priority setting in the health system: an update from WHO CHOICE. Int J Health Policy Manag. 2021;10(11):673\u2013677.","journal-title":"Int J Health Policy Manag"},{"key":"e_1_3_6_58_1","unstructured":"National Institute for Health and Care Excellence. DSU technical support document 14: survival analysis for economic evaluations alongside clinical trials - extrapolation with patient-level data. 2022. https:\/\/www.sheffield.ac.uk\/nice-dsu"},{"key":"e_1_3_6_59_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737167.2016.1146594"},{"key":"e_1_3_6_60_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-020-01564-0"},{"key":"e_1_3_6_61_1","unstructured":"Koruth R Sharma R Kanters S et\u00a0al. Establishing the relationship between relapse-free survival and overall survival in adjuvant high-risk radically resected cutaneous melanoma. In: The Society for Melanoma Research Fifteenth International Congress Manchester England 2018."},{"key":"e_1_3_6_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00559-9"},{"key":"e_1_3_6_63_1","unstructured":"National Institute for Health and Care Excellence. Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma: Technology appraisal guidance [TA837]. 2022. https:\/\/www.nice.org.uk\/guidance\/TA837"},{"key":"e_1_3_6_64_1","unstructured":"Hematology\/Oncology. Adjuvant pembrolizumab shows benefit in patients with resected stage IIB IIC melanoma. 2022. https:\/\/www.healio.com\/news\/hematology-oncology\/20220606\/adjuvant-pembrolizumab-shows-benefit-in-patients-with-resected-stage-iib-iic-melanoma"},{"key":"e_1_3_6_65_1","unstructured":"Goodman A. Adjuvant pembrolizumab for high-risk stage II melanoma: Efficacy and safety examined. 2022. https:\/\/ascopost.com\/news\/september-2021\/adjuvant-pembrolizumab-for-high-risk-stage-ii-melanoma-efficacy-and-safety-examined\/#:\u223c:text=The%20current%20standard%20of%20care stage%20IIIA%20and%20IIIB%20melanoma"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2023.2174748","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T10:17:32Z","timestamp":1701944252000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2023.2174748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,15]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,12,31]]}},"alternative-id":["10.1080\/13696998.2023.2174748"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2023.2174748","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,15]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-12-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}